Pfizer Inc. (NYSE:PFE) Position Cut by MainStreet Investment Advisors LLC

MainStreet Investment Advisors LLC trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 5.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 224,541 shares of the biopharmaceutical company’s stock after selling 12,119 shares during the quarter. MainStreet Investment Advisors LLC’s holdings in Pfizer were worth $8,265,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of PFE. Kinloch Capital LLC bought a new position in Pfizer in the 4th quarter worth approximately $25,000. Penbrook Management LLC bought a new position in Pfizer in the 4th quarter worth approximately $27,000. Cedar Mountain Advisors LLC grew its holdings in Pfizer by 55.4% in the 4th quarter. Cedar Mountain Advisors LLC now owns 842 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 300 shares in the last quarter. Insight Financial Services bought a new position in Pfizer in the 4th quarter worth approximately $33,000. Finally, Flagship Private Wealth LLC bought a new position in Pfizer in the 4th quarter worth approximately $41,000. 67.36% of the stock is owned by institutional investors and hedge funds.

A number of equities analysts recently issued reports on PFE shares. DZ Bank reissued a “buy” rating and issued a $41.00 price objective on shares of Pfizer in a report on Wednesday, February 3rd. Morgan Stanley decreased their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Friday, January 29th. Royal Bank of Canada set a $42.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Monday, January 4th. The Goldman Sachs Group set a $40.00 target price on Pfizer and gave the stock a “neutral” rating in a research report on Thursday, January 21st. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating and set a $37.00 target price for the company in a research report on Thursday, October 29th. Eleven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Pfizer presently has an average rating of “Hold” and a consensus price target of $39.38.

Shares of NYSE:PFE traded down $0.43 on Tuesday, reaching $33.83. 587,009 shares of the company traded hands, compared to its average volume of 35,504,273. Pfizer Inc. has a fifty-two week low of $27.88 and a fifty-two week high of $43.08. The company’s 50 day moving average is $35.94 and its 200-day moving average is $37.10. The stock has a market capitalization of $188.04 billion, a PE ratio of 22.10, a P/E/G ratio of 2.79 and a beta of 0.70. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.40 and a quick ratio of 1.13.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.04). Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The company had revenue of $11.68 billion for the quarter, compared to analyst estimates of $11.32 billion. During the same quarter last year, the company posted $0.55 EPS. Pfizer’s revenue was up 11.8% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.89 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 5th. Stockholders of record on Friday, January 29th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 4.61%. The ex-dividend date of this dividend is Thursday, January 28th. This is an increase from Pfizer’s previous quarterly dividend of $0.38. Pfizer’s dividend payout ratio is 52.88%.

Pfizer Profile

Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.

Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.